CTRI/2023/03/050853已完成Unknown
A pilot randomized, double-blind, placebo-controlled, parallel-group clinical study to evaluate the safety and tolerability of BioPB-01 in healthy adults
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Participants who are 25 to 55 years of age (inclusive) at the time of signing the informed consent form.
- •2. Participants having good general health (no active or uncontrolled diseases, infections, or conditions).
- •3. BMI within the range of 24.9 to 34.9 kg/m2 (inclusive).
- •4. Random blood glucose level <140 mg/dL.
- •5. Concurrent metformin use is acceptable for indications other than diabetes. (However, the subject and investigator must not change metformin dosing during the three weeks of the study).
- •6. Non-pregnant and non-lactating females of childbearing potential who agree to use adequate contraception/sexual abstinence throughout the study period.
- •7. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.
- •8. Individuals with access to a digital device to fill out the questionnaires.
排除标准
- •1. Participant has a history of uncontrolled hypertension (i.e., =150 mmHg systolic and/or =110 mmHg diastolic).
- •2. Participant with history of post-prandial hypoglycemia (occurring 2-5 hours after food intake) of unknown cause.
- •3. Abnormal thyroid-stimulating hormone (TSH) levels ( <0.4 or > 4.2 µIU/ml).
- •4. Known case of Type 1 or 2 diabetes.
- •5. Participant has a history of heart disease and/or cardiovascular disease, kidney disease (dialysis or renal failure), and/or hepatic impairment or disease.
- •6. Participant has a history of previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the year prior to screening, immune disorder (i.e., HIV/AIDS), or a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to the screening visit.
- •7. Received a vaccine for COVID-19 or any other vaccination in the 2 weeks prior to screening or planned during the study period, current COVID-19 infections, or currently have the post COVID-19 condition as defined by the World Health Organization (WHO) (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis).
- •8. Have a known intolerance, sensitivity, or allergy to any of the study products, their ingredients, or any excipients used in the formulation.
- •9. Individuals who have a known history of diverticulitis.
- •10. Have a known intolerance, sensitivity, or allergy to milk or soy.
- •11. Any condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the participant or the quality of the study data.
- •12. Currently taking dietary supplements other than vitamins and minerals.
- •13. Taking any other prescription medication at the time of randomization that is known to impact blood sugar and or blood sugar metabolism, as per the Principal Investigator’s (PI) discretion.
- •14. History of smoking, alcohol (heavy drinking as defined by NIAAA [National Institute on Alcohol Abuse and Alcoholism], USA), or substance abuse in the 12 months prior to screening.
- •15. Receipt or use of an investigational product in another research study within 30 days prior to baseline/Visit 2.
研究者
相似试验
进行中（未招募）
1 期
Study to define the optimal dose, to evaluate efficacy, safety and tolerability of self- administered subcutaneous diclofenac sodium 25-50-75mg/1ml in the treatment of an acute migraine attack with headache.Acute migraine attacks with headache.MedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-004828-29-ITIBSA INSTITUT BIOCHIMIQUE SA128
进行中（未招募）
1 期
A pilot study of the use of metformin to reduce airway glucose in COPDChronic obstructive pulmonary diseaseMedDRA version: 21.1 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2018-001755-12-GBImperial College40
进行中（未招募）
不适用
A pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, phase IIa study to determine the clinical safety/tolerability and exploratory efficacy of EHT 0202 (40 and 80 mg bid) as adjunctive therapy to acetylcholinesterase inhibitor over a 3-month period in ambulatory patients suffering from mild to moderate Alzheimer’s Disease (EHT 0202/002 protocol).EUCTR2007-005549-39-FREXONHIT
进行中（未招募）
不适用
A pilot, randomized, double-blind, placebo-controlled, crossoverstudy evaluating the efficacy and safety of Vardenafil versusplacebo administered 12, 18 and 24 hours prior to initiation ofsexual intercourse in subjects with ED.ERECTILE DISFUNCTIONMedDRA version: 6.1Level: PTClassification code 10061461EUCTR2004-001549-13-ITGLAXO SMITHKLINE314
已完成
不适用
A pilot, double-blind, randomised, placebo-controlled, exploratory study to investigate the safety and effect of calf intestinal Alkaline Phosphatase in patients with SEPsisInfections and InfestationsOther and unspecified infectious diseasesSepsisISRCTN49482187AM-Pharma B.V. (Netherlands)32